



## Praxis Precision Medicines to Participate in Upcoming Fireside Chat

November 20, 2025 at 4:01 PM EST

BOSTON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- [Praxis Precision Medicines](#), Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that HCWainwright analyst Doug Tsao will host an expert call on **Deep Dive into Praxis' Ulixacaltamide Data** with statistician Prof. Chuck McCullogh, University of California, San Francisco on November 24, 2025 at 1:00pm EST which will be joined by Marcio Souza, Praxis' CEO.

The registration link can be found [here](#).

### About Praxis

Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across epilepsy and movement disorders, with four clinical-stage product candidates. For more information, please visit [www.praxismedicines.com](http://www.praxismedicines.com) and follow us on [Facebook](#), [Instagram](#), [LinkedIn](#) and [Twitter/X](#).

### Investor Contact:

Praxis Precision Medicines  
investors@praxismedicines.com  
857-702-9452

### Media Contact:

Dan Ferry  
Life Science Advisors  
Daniel@lifesciadvisors.com  
617-430-7576